Business
Results for the six months ended 30 September 2025
Eco Animal Health Group plc reported a strong first half with revenue increasing 19% to £39.4 million, driven by significant growth in the USA and Canada (up 30% to £11.2 million) and a recovery in China and Japan (up 48% to £12.1 million). Gross margins improved substantially to 49.6% from 40.3%, leading to adjusted EBITDA of £3.0 million, a considerable increase from £0.4 million in the prior year. The company also received a positive opinion from the EMA for its poultry vaccine ECOVAXXIN® MS, with an anticipated EU commercial launch in the second half of 2026. The company expects full-year results to be in line with market expectations. Disclaimer*
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n 1 December 2025\nECO Animal Health Group plc\nResults for the six months ended 30 September 2025\nRevenues ahead of guidance, with improved gross margins driving greater profitability\nECO Animal Health Group plc (\"ECO\", the \"Company\", or the \"Group\") (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary research and development (\"R&D\") pipeline, today announces its unaudited interim results for the six months ended 30 September 2025. As a result of increased volume plus price improvements and lower cost of sales, revenue and adjusted EBITDA are ahead of the Board's previously announced guidance set out in the 25 September 2025 AGM Trading Update.\nHIGHLIGHTS\nFinancial\n \n· Group Revenue increased 19% to £39.4 million (H1 2024: £33.2 million)\no Revenues on a constant currency basis increased 23%\no Revenue in USA and Canada increased by 30% to £11.2 million (H1 2024: £8.6 million)\no Revenue in China and Japan recovered strongly, showing an increase of 48% to £12.1 million (H1 2024: £8.2 million)\n· Gross margins increased to 49.6% (H1 2024: 40.3%), driven by improved pricing and lower input costs\n· Adjusted EBITDA at £3.0 million (H1 2024: £0.4 million)\n· Loss per share of 0.54p (H1 2024: loss per share: 2.50p)\n· Cash generated by operations before working capital increased to £4.5 million (H1 2024: £0.8 million)\n· Cash balances increased to £18.6 million (30 September 2024: £18.3 million)\n \nOperational (including post-period end)\n \n· Positive Opinion received ahead of schedule from the European Medicines Agency EMA for ECOVAXXIN® MS, the Group's poultry vaccine against Mycoplasma synoviae, establishing an anticipated EU commercial launch in H2 CY2026\n· Other late-stage projects for poultry and swine continued to progress towards regulatory submission broadly according to plan, with launches planned for 2026 and 2027\n \nDavid Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: \"We are delighted to report on a per...